Open Access Open Badges Research

Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes

Hee Kyung Ahn1, Yeon Hee Park1, Su Jin Lee1, Silvia Park1, Chi Hoon Maeng1, Won Park2, Doo Ho Choi2, Seung Jae Hur2, Jin Seok Ahn1 and Young-Hyuck Im1*

  • * Corresponding author: Young-Hyuck Im

  • † Equal contributors

Author Affiliations

1 Division of Hematology-Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu Seoul, 135-710, Korea

2 Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

For all author emails, please log on.

SpringerPlus 2013, 2:136  doi:10.1186/2193-1801-2-136

Published: 28 March 2013


The aims of the present study were to investigate how breast cancer (BC) subtypes and treatment affect time to brain metastasis (TTBM). We retrospectively investigated 189 consecutive patients who were diagnosed with brain metastasis (BM) from BC between 2000 and 2009 at Samsung Medical Center. We analyzed TTBM from initial diagnosis of metastatic BC according to subtypes and trastzumab (T) administration before BM diagnosis. The median age of 189 BM patients from BC was 48 years. We divided TTBM into four groups considering BC subtypes and treatment; HR-positive/HER2-negative (n=45), HER2-positive with T before BM development (n=47), HER2-positive without T before BM development (n=39), and TNBC (n=58). The median TTBMs for each group were 17.5 months, 13.7 months, 5.8 months, and 2.9 months, respectively (p<0.001). HER2-positive without T (HR 1.892, p=0.008) and TNBC (HR 1.652, p=0.023) were independently associated with shorter TTBM. In multivariate analysis, HER2-positive without T (hazard ratio 1.725, p=0.002) and TNBC (hazard ratio 1.579, p=0.022) were independent risk factors for worse metastatic OS compared with HR-positive/HER2-negative subtype. TTBMs were shorter in patients with HER2-positive without T and TNBC among BC subtypes. Prospective clinical study for high risk patients for early BM is warranted.

Breast cancer; Brain metastases; HER2; Triple negative; Trastuzumab